Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Cyclospora cayetanensis, the most common co-covered peer. We currently track 1 Biotech story that mention Dr. Natasha Bagdasarian, all published on July 12, 2026.
Last mentioned: Jul 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Cyclospora cayetanensis, the most common co-covered peer. We currently track 1 Biotech story that mention Dr. Natasha Bagdasarian, all published on July 12, 2026. Each carries 6 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Natasha Bagdasarian. Shared-story counts are live from our verified record — not editorial picks.
With 992 infections in Michigan, the cyclospora outbreak creates urgent demand for antibiotic supplies and spotlights the need for novel antiparasitic therapies, presenting both short-term and long-term opportunities for biopharma.
Source: sandiegouniontribune.com · orlandosentinel.com
Dr. Natasha Bagdasarian is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
